Literature DB >> 3838318

Studies on the mechanism of Sn-protoporphyrin suppression of hyperbilirubinemia. Inhibition of heme oxidation and bilirubin production.

C S Simionatto, K E Anderson, G S Drummond, A Kappas.   

Abstract

The synthetic heme analogue Sn-protoporphyrin is a potent competitive inhibitor of heme oxygenase, the rate-limiting enzyme in heme degradation to bile pigment, and can entirely suppress hyperbilirubinemia in neonatal animals and significantly reduce plasma bilirubin levels in a variety of circumstances in experimental animals and man. To further explore the mechanism by which this metalloporphyrin reduces bilirubin levels in vivo, we have examined its effects on bilirubin production in bile duct-cannulated rats, in which bilirubin derived from heme catabolism is known to be rapidly excreted in bile. The administration of Sn-protoporphyrin (10-50 mumol/kg body weight) was followed by prompt (within approximately 1 h) and sustained (up to at least 18 h) decreases in bilirubin output, to levels 25-30 percent below the levels of bilirubin output in control bile fistula animals. The metalloporphyrin had no effect on bile flow or the biliary output of bile acids. Infusions of heme, which is taken up primarily in hepatocytes, or of heat-damaged erythrocytes, which are taken up in reticuloendothelial cells, resulted in marked increases in bilirubin output in bile in control animals; these increases were completely prevented or substantially diminished by Sn-protoporphyrin administration. By contrast, the metalloporphyrin did not alter the high levels of bilirubin in plasma and bile that were achieved in separate experiments by the constant (16 h) infusion of unconjugated bilirubin to bile duct-cannulated rats. Thus, Sn-protoporphyrin exerts no major effects on the metabolic disposition of preformed bilirubin. Heme oxygenase activities were markedly decreased in microsomal preparations from liver, spleen, and kidneys in these experiments, to a degree comparable to the decreases we have observed in the intact rat. We also demonstrated that a substantial proportion (19-35%) of a dose of Sn-protoporphyrin is promptly excreted in bile and that the time course of biliary excretion of this compound more closely reflects plasma concentrations of the metalloporphyrin, which decline rapidly, rather than concentrations in liver, which are considerably more persistent. These results indicate that Sn-protoporphyrin substantially reduces the in vivo production of bilirubin from the degradation of endogenous as well as exogenous heme in the rat. Moreover, this inhibitory effect of the synthetic metalloporphyrin on bilirubin production occurs in both hepatocytes and reticuloendothelial cells, which are the major tissue sites for bilirubin formation. In other studies, we have established that heme oxygenase blockade by Sn-protoporphyrin leads to a marked and rapid excretion of heme into bile presumably because the synthetic metabolism to bile pigment and making it available for excretion via the biliary system in to the gut, These studies strongly suggest that Sn-protoporphyrin diminishes hyperbilirubinemia in animals and man by inhibiting the production of the bile pigment in vivo, and that its principal mode of action involves a potent and sustained competitive inhibition of heme oxygenase.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3838318      PMCID: PMC423526          DOI: 10.1172/JCI111727

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  36 in total

1.  The enzymatic catabolism of hemoglobin: stimulation of microsomal heme oxygenase by hemin.

Authors:  R Tenhunen; H S Marver; R Schmid
Journal:  J Lab Clin Med       Date:  1970-03

2.  The enhancement of maximal bilirubin excretion with taurocholate-induced increments in bile flow.

Authors:  C A Goresky; H H Haddad; W S Kluger; B E Nadeau; G G Bach
Journal:  Can J Physiol Pharmacol       Date:  1974-06       Impact factor: 2.273

3.  Storage iron kinetics. II. The uptake of hemoglobin iron by hepatic parenchymal cells.

Authors:  C Hershko; J D Cook; C A Finch
Journal:  J Lab Clin Med       Date:  1972-11

4.  Hemoglobin and erythrocyte catabolism in rat liver: the separate roles of parenchymal and sinusoidal cells.

Authors:  D M Bissell; L Hammaker; R Schmid
Journal:  Blood       Date:  1972-12       Impact factor: 22.113

5.  Tissue localization of the heme-hemopexin complex in the rabbit and the rat as studied by light microscopy with the use of radioisotopes.

Authors:  U Muller-Eberhard; C Bosman; H H Liem
Journal:  J Lab Clin Med       Date:  1970-09

6.  Accelerated conversion of heme to bile pigments caused in the liver by carbon disulfide and other sulfur-containing chemicals.

Authors:  J Järvisalo; A H Gibbs; F de Matteis
Journal:  Mol Pharmacol       Date:  1978-11       Impact factor: 4.436

7.  Effect of porphyrinogenic agents on protein synthesis and bilirubin formation by the isolated perfused rat liver.

Authors:  H H Liem; K Miyai; U Muller-Eberhard
Journal:  Biochim Biophys Acta       Date:  1977-01-24

8.  Tin protoporphyrin inhibits carbon monoxide production in adult mice.

Authors:  G S Milleville; M D Levitt; R R Engel
Journal:  Pediatr Res       Date:  1985-01       Impact factor: 3.756

9.  Tin-protoporphyrin suppression of hyperbilirubinemia in mutant mice with severe hemolytic anemia.

Authors:  S Sassa; G S Drummond; S E Bernstein; A Kappas
Journal:  Blood       Date:  1983-05       Impact factor: 22.113

10.  Prevention of neonatal hyperbilirubinemia by tin protoporphyrin IX, a potent competitive inhibitor of heme oxidation.

Authors:  G S Drummond; A Kappas
Journal:  Proc Natl Acad Sci U S A       Date:  1981-10       Impact factor: 11.205

View more
  11 in total

Review 1.  HO-1 overexpression and underexpression: Clinical implications.

Authors:  George S Drummond; Jeffrey Baum; Menachem Greenberg; David Lewis; Nader G Abraham
Journal:  Arch Biochem Biophys       Date:  2019-08-16       Impact factor: 4.013

2.  Effect of heme arginate administration on blood pressure in spontaneously hypertensive rats.

Authors:  R D Levere; P Martasek; B Escalante; M L Schwartzman; N G Abraham
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

3.  Sn-protoporphyrin inhibition of fetal and neonatal brain heme oxygenase. Transplacental passage of the metalloporphyrin and prenatal suppression of hyperbilirubinemia in the newborn animal.

Authors:  G S Drummond; A Kappas
Journal:  J Clin Invest       Date:  1986-03       Impact factor: 14.808

Review 4.  Control of heme metabolism with synthetic metalloporphyrins.

Authors:  A Kappas; G S Drummond
Journal:  J Clin Invest       Date:  1986-02       Impact factor: 14.808

Review 5.  A review of new approaches to assessing hepatic function in animals.

Authors:  C E Cornelius
Journal:  Vet Res Commun       Date:  1987       Impact factor: 2.459

6.  Effects of age, phenobarbital, beta-naphthoflavone and dexamethasone on rat hepatic heme oxygenase.

Authors:  A Plewka; M Bienioszek
Journal:  Arch Toxicol       Date:  1994       Impact factor: 5.153

7.  Dual control mechanism for heme oxygenase: tin(IV)-protoporphyrin potently inhibits enzyme activity while markedly increasing content of enzyme protein in liver.

Authors:  M K Sardana; A Kappas
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

8.  Sn-protoporphyrin suppresses chemically induced experimental hepatic porphyria. Potential clinical implications.

Authors:  R A Galbraith; G S Drummond; A Kappas
Journal:  J Clin Invest       Date:  1985-12       Impact factor: 14.808

9.  Sn-protoporphyrin blocks the increase in serum bilirubin levels that develops postnatally in homozygous Gunn rats.

Authors:  T R Sisson; G S Drummond; D Samonte; R Calabio; A Kappas
Journal:  J Exp Med       Date:  1988-03-01       Impact factor: 14.307

10.  Long-term administration of massive doses of Sn-protoporphyrin in anemic mutant mice (sphha/sphha).

Authors:  S Sassa; G S Drummond; S E Bernstein; A Kappas
Journal:  J Exp Med       Date:  1985-09-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.